Laryngeal Diffuse Large B-Cell Lymphoma Staging and Treatment

Diagnostic Confirmation

The American Society of Clinical Oncology recommends obtaining adequate tissue for diagnosis through excisional biopsy or sufficient core biopsy of the laryngeal lesion, as laryngeal lymphomas can be diagnostically challenging 1, 2
A mandatory immunohistochemistry panel must include CD45, CD20, and CD3 to confirm B-cell lineage and CD20 positivity, which is essential for rituximab eligibility 1, 3

The National Comprehensive Cancer Network recommends a complete blood count and comprehensive metabolic panel, including lactate dehydrogenase (LDH) and uric acid, for all patients with laryngeal diffuse large B-cell lymphoma 1, 2, 3
Screening for HIV, hepatitis B, and hepatitis C is required, as these infections impact treatment decisions and prognosis 1, 2, 3
The European Society for Medical Oncology recommends CT scan of chest and abdomen as the minimum required imaging for all patients amenable to curative therapy 1, 2, 3
PET scanning is strongly recommended to better delineate disease extent and for subsequent treatment response evaluation according to revised criteria 1, 2, 3

The Ann Arbor staging system should be used to classify disease extent, with stages defined as follows:

The International Prognostic Index (IPI) and age-adjusted IPI (aa-IPI) should be calculated using age, elevated LDH, ECOG performance status, Ann Arbor stage, and number of extranodal sites, with higher scores indicating a need for more aggressive treatment approaches 1, 2, 3

For younger patients (≤60 years) with low-intermediate risk (aa-IPI ≤1), six to eight cycles of R-CHOP-21 is the standard approach, with consideration of radiotherapy to sites of previous bulky disease in patients with bulky presentation 1, 4, 5
For patients aged 60-80 years, eight cycles of R-CHOP-21 is the current standard, regardless of risk category, with no demonstrated survival advantage of R-CHOP-14 over R-CHOP-21 1, 6, 7
Comprehensive geriatric assessment is recommended to determine treatment intensity for patients >80 years, with modified R-COP at reduced doses potentially appropriate for those with cardiac dysfunction 6

Dose reductions due to hematological toxicity should be avoided, with prophylactic hematopoietic growth factors used to maintain dose intensity 1, 2, 3
Tumor lysis syndrome risk should be assessed in patients with high tumor burden, with prednisone prephase treatment administered as prophylaxis 1, 2, 5